Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items turns positive
Q1 FY2026 other non-cash items was $4.81M, compared with -$8.35M a year earlier. Trailing-twelve-month other non-cash items was $11.87M.
Context
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other non-cash items holds near $4.81M or moves back toward the trailing-twelve-month quarterly average of $2.97M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- (2.02M) USD
- Year-over-year change
- -134.8%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.02M) | -134.8% |
| FY2024 | 2024-12-31 | 5.8M | -43.7% |
| FY2023 | 2023-12-31 | 10.3M | +48961.9% |
| FY2022 | 2022-12-31 | 21K | -99.4% |
| FY2021 | 2021-12-31 | 3.38M | — |
Other Non-Cash Items vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +180.6% is the 5th highest of 10, against a peer median of +14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CBUSCibus, Inc. | LTM Mar 2026 | $46.54M USD | -79.4% | — | 1085.8% |
| LTM Mar 2026 | $39.12M USD | +2806.7% | — | 994.5% | |
| LTM Mar 2026 | $12.57M USD | -582.5% | — | — | |
| LTM Mar 2026 | $11.87M USD | +180.6% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.27M USD | +14.2% | +214.5% | — |
| LTM Mar 2026 | $3.61M USD | +627.4% | — | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$1.58M CAD | -95.6% | — | 8.6% |
| LTM Mar 2026 | $952K USD | -137.7% | -20.3% | 0.4% | |
| LTM Mar 2026 | $595K USD | +331.5% | -76.4% | — | |
| LTM Mar 2026 | $371K USD | +396.8% | — | — | |
| Peer median (excluding UNCY) | — | +14.2% | -20.3% | 501.6% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 966K | 1.05M | 1.77M | 2.35M | 2.64M |
| Change in Working Capital | (105K) | 1.18M | (93K) | (427K) | (5.95M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.24M | 1.27M | 1.28M | 790K | (2.51M) |
| Other Working Capital | (1.35M) | (89K) | (1.37M) | (1.22M) | (3.45M) |
| Other Non-Cash Items | 3.38M | 21K | 10.3M | 5.8M | (2.02M) |
| Operating Cash Flow | (5.77M) | (15.65M) | (18.28M) | (28.58M) | (31.32M) |
| Capital Expenditures | (29K) | (2K) | (12K) | (72K) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (12.07M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (29K) | (2K) | (12K) | (72K) | (12.1M) |
| Debt Repayment | (15K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 22.27M | 11K | 0 | 683K | 48.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.1M) | 0 |
| Other Financing Activities | 119K | (482K) | (2.65M) | (4.5M) | (1.61M) |
| Financing Cash Flow | 22.38M | (471K) | 27.54M | 45.09M | 46.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.58M | (16.12M) | 9.25M | 16.44M | 3.06M |
| Free Cash Flow | (5.8M) | (15.65M) | (18.3M) | (28.65M) | (31.34M) |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.